636 studies on GLP-1 agonist class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This planned study holds significant promise, as it could establish a novel pharmacological strategy to improve outcomes for atrial fibrillation patients with obesity undergoing ablation. If successful, the findings w…
This research is significant because it explores a novel therapeutic approach for acute pulmonary embolism, a condition with limited long-term treatment options beyond anticoagulation. If Semaglutide demonstrates a po…
Understanding the long-term impact of semaglutide on appetite and eating behavior is crucial for optimizing obesity treatment strategies. If the study demonstrates sustained improvements in these areas, it could provi…
This foundational Phase 1 study is a critical early step in the development of NN9535 (semaglutide), a compound now widely known for its efficacy in type 2 diabetes and obesity. The successful completion of this trial…
This study is significant because it evaluates a novel approach to personalizing semaglutide treatment, which could revolutionize how obesity and excess weight are managed. By providing healthcare professionals with a…
The successful completion of this trial could have significant implications for the treatment landscape of Type 2 Diabetes. If QLG2065 demonstrates comparable efficacy and safety to Ozempic®, it would introduce a new,…
This study is significant because Semaglutide, a GLP-1 receptor agonist, is already approved for obesity and type 2 diabetes, conditions strongly linked to NAFLD. If the results demonstrate efficacy, it could provide …
The resurgence of cocaine use and related mortality underscores an urgent, unmet need for effective treatments. If Semaglutide proves effective in this pilot study, it could offer a novel pharmacological approach to C…
This study holds significant promise for identifying a novel therapeutic approach for alcohol use disorder (AUD), especially in the context of obesity and fatty liver disease, which are highly prevalent comorbidities.…
As this is a planned study, no results are available yet. However, the researchers anticipate that CagriSema will demonstrate significant improvements in key metabolic markers compared to placebo.
The potential success of this combination therapy could represent a significant advancement in the treatment landscape for obesity and overweight. By potentially enhancing the already impressive effects of tirzepatide…
This pilot study is significant because it explores a novel adjunctive therapeutic strategy for Crohn's disease by targeting metabolic health and weight. If successful, it could demonstrate that GIP/GLP-1 receptor ago…
Understanding the precise mechanisms by which Tirzepatide impacts pancreatic alpha and beta cell function and insulin sensitivity is critically important. This mechanistic insight can refine our understanding of optim…
The withdrawal of this study means a potential avenue for exploring enhanced weight loss and metabolic improvements, particularly through muscle preservation with Bimagrumab alongside Tirzepatide's established effects…
Persistent obesity after bariatric surgery represents a significant clinical challenge, often leading to comorbidities and reduced quality of life. If Tirzepatide proves effective and safe in this specific patient pop…
This foundational Phase 1 study is crucial for the development of tirzepatide, providing essential data on its pharmacokinetics and safety in humans. Understanding how the drug is absorbed, distributed, metabolized, a…
This pilot study is critically important as it addresses a significant unmet medical need for safe and effective weight management in obese kidney transplant recipients. Successful outcomes could establish Tirzepatide…
Understanding the extrapancreatic effects of GIP and GLP-1 is crucial for optimizing current and developing future treatments for type 2 diabetes and obesity. This research will provide critical insights into why comb…
This study is incredibly significant because it seeks to confirm if tirzepatide, a dual GLP-1 and GIP receptor agonist already approved for weight management, can directly improve long-term health outcomes beyond just…
The potential for tirzepatide, a dual GLP-1 and GIP receptor agonist, to address both obesity and methamphetamine use disorder simultaneously represents a significant advancement in addiction medicine and metabolic he…
Obtaining real-world data on Tirzepatide is paramount for understanding its performance and tolerability outside the highly controlled environment of earlier clinical trials. This study will provide invaluable insight…
The potential to preserve lean mass during GLP-1 induced weight loss is crucial for improving long-term health outcomes and metabolic function in individuals with obesity. Preventing muscle loss can enhance strength, …
If successful, this pilot study could reveal a novel therapeutic application for tirzepatide, potentially offering significant relief for post-menopausal women with obesity suffering from vasomotor symptoms. Beyond sy…
As this is a recruiting clinical trial, specific results are not yet available; however, the study aims to demonstrate significant improvements in key health metrics. Researchers hypothesize that preoperative tirzepat…
The successful integration of tirzepatide with automated insulin delivery could represent a paradigm shift in Type 1 Diabetes management, offering a novel strategy to improve glucose control beyond current capabilitie…
The provided research record is a study protocol description from ClinicalTrials.gov and, as such, does not contain specific efficacy or safety results from the trial. The study, NCT06445075, is listed as COMPLETED, i…
The study aimed to demonstrate that tirzepatide significantly impacts food intake and modulates brain activity in areas associated with appetite and reward. While specific quantitative results are not detailed in this…
This planned study is significant because it aims to explore a novel therapeutic avenue for a highly complex patient population: individuals with obesity and chronic kidney failure. If Tirzepatide demonstrates a favor…
Successfully demonstrating the feasibility and efficacy of tirzepatide for weight loss in early-stage HR+/Her2- breast cancer patients could represent a significant advancement in supportive cancer care. Effective wei…
This Phase 3 trial is highly significant as it directly compares Tirzepatide, a novel dual GIP/GLP-1 receptor agonist, against a standard rapid-acting insulin, insulin lispro (U100), in a challenging patient populatio…
This study is critically important as it will provide a head-to-head comparison of the most effective current treatments for obesity, offering invaluable data for clinical decision-making. If Semaglutide or Tirzepatid…
The findings of this study are crucial for enhancing patient safety during surgical procedures for individuals on GLP-1/GIP agonists. If standard fasting guidelines prove insufficient, it could lead to revised pre-ope…
The potential for tirzepatide, a drug primarily known for its efficacy in type 2 diabetes and weight management, to treat Hidradenitis Suppurativa is highly significant. If successful, this study could repurpose an ex…